Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Surveillance imaging at 45 to 90 days after transcatheter left atrial appendage occlusion device implantation with transesophageal echocardiography (TEE) or cardiac computed tomography (CT) is recommended to assess device position and the presence of device-related complications such as device-related thrombus (DRT) or peridevice leak. Detection of DRT is associated with a significantly increased risk of a stroke or systemic embolization event within 6 months of detection. Nonetheless, there is significant variability in detection of DRT as a result of timing, frequency, and imaging modality used for surveillance. The process of DRT formation vs benign device endothelization is not known. Here we highlight the spectrum of imaging findings seen on TEE and CT and emphasize the need for unified definitions and standardized reporting of imaging findings.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11602609PMC
http://dx.doi.org/10.1016/j.jaccas.2024.102661DOI Listing

Publication Analysis

Top Keywords

device-related thrombus
8
detection drt
8
imaging findings
8
imaging
5
imaging spectrum
4
spectrum device-related
4
thrombus percutaneous
4
percutaneous left atrial appendage
4
left atrial appendage occlusion
4
occlusion surveillance
4

Similar Publications

Background: Left atrial appendage closure with the Watchman FLX Pro device (Boston Scientific) is an alternative to anticoagulation in patients at high bleeding risk with atrial fibrillation. Intraprocedural thrombus formation is rare and poses a unique challenge.

Case Summary: A 57-year-old man with paroxysmal atrial fibrillation and prior intracranial hemorrhage underwent elective left atrial appendage closure.

View Article and Find Full Text PDF

Introduction: Percutaneous left atrial appendage closure (LAAC) reduces the risk of thromboembolic stroke in patients with non-valvular atrial fibrillation who cannot tolerate long-term oral anticoagulation. However, outcomes after LAAC in patients requiring chronic immunosuppressive therapy (IMS) remain unknown. This study aimed to investigate the perioperative and long-term outcomes of percutaneous LAAC in patients receiving chronic IMS.

View Article and Find Full Text PDF

Background: Direct current cardioversion (DCCV) is commonly used for rhythm control in atrial fibrillation (AF). Left atrial appendage occlusion (LAAO) provides stroke prevention in patients with contraindications to oral anticoagulation (OAC), but the safety of DCCV without periprocedural anticoagulation in this group remains uncertain.

Objective: To evaluate the safety of performing DCCV without systemic anticoagulation in patients with prior LAAO.

View Article and Find Full Text PDF

Embolic stroke of undetermined source (ESUS) is a clinical event with an undelineated embolic etiology after the initial stroke workup. Once stroke specialists confirm ESUS, evaluation of rhythm disorders such as atrial fibrillation, specific cardiac pathologies (cardiomyopathy, left atrial cardiopathy, left-atrial septal pouch, aortic or mitral valve disease, cardiac neoplasm, right-to-left shunts, or device-related thrombus), and acquired hypercoagulable states, which may occasionally be related to malignancy, should be performed. While most ESUS patients require appropriate antiplatelet therapy, certain subsets may require oral anticoagulation.

View Article and Find Full Text PDF